Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCAX Bicara Therapeutics	$8.71 -1.1%	$12.06	$7.80 ▼ $28.09	$475.01M	N/A	598,644 shs	2.70 million shs
BYSI BeyondSpring	$2.45 -2.8%	$2.01	$0.98 ▼ $3.44	$98.77M	0.07	32,461 shs	33,027 shs
KURA Kura Oncology	$5.67 -1.0%	$6.17	$5.41 ▼ $23.48	$490.88M	0.4	1.24 million shs	3.33 million shs
MGTX MeiraGTx	$6.61 -0.9%	$5.97	$3.85 ▼ $8.75	$531.21M	1.16	384,804 shs	928,477 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCAX Bicara Therapeutics	-1.14%	-6.55%	-7.93%	-35.00%	+870,999,900.00%
BYSI BeyondSpring	-2.78%	-22.71%	+43.70%	+70.14%	+0.41%
KURA Kura Oncology	-1.05%	-3.08%	+2.16%	-19.57%	-72.48%
MGTX MeiraGTx	-0.90%	+4.26%	+29.61%	-9.82%	+57.01%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BCAX Bicara Therapeutics	2.1533 of 5 stars	3.5	0.0	0.0	0.0	1.5	0.8	1.3
BYSI BeyondSpring	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
KURA Kura Oncology	4.533 of 5 stars	4.4	3.0	0.0	4.7	2.0	0.8	0.6
MGTX MeiraGTx	4.3909 of 5 stars	3.5	2.0	0.0	4.8	3.0	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCAX Bicara Therapeutics	3.00	Buy	$31.86	265.77% Upside
BYSI BeyondSpring	0.00	N/A	N/A	N/A
KURA Kura Oncology	2.86	Moderate Buy	$24.50	332.10% Upside
MGTX MeiraGTx	3.00	Buy	$24.00	263.09% Upside

Current Analyst Ratings Breakdown

Latest BYSI, MGTX, BCAX, and KURA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	KURA Kura Oncology	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
6/20/2025	KURA Kura Oncology	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$36.00
6/4/2025	KURA Kura Oncology	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$28.00
5/23/2025	BCAX Bicara Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underweight ➝ Equal Weight	$8.00
5/23/2025	BCAX Bicara Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$30.00
5/19/2025	KURA Kura Oncology	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$32.00 ➝ $30.00
5/16/2025	BCAX Bicara Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$44.00 ➝ $41.00
5/14/2025	MGTX MeiraGTx	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$38.00 ➝ $35.00
5/2/2025	KURA Kura Oncology	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$32.00 ➝ $11.00
4/29/2025	KURA Kura Oncology	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$28.00 ➝ $28.00
4/28/2025	KURA Kura Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00 ➝ $40.00

(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCAX Bicara Therapeutics	N/A	N/A	N/A	N/A	$9.04 per share	N/A
BYSI BeyondSpring	$1.75M	56.45	N/A	N/A	($0.37) per share	-6.62
KURA Kura Oncology	$53.88M	9.11	N/A	N/A	$5.32 per share	1.07
MGTX MeiraGTx	$33.28M	15.96	N/A	N/A	$0.87 per share	7.60

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCAX Bicara Therapeutics	-$68M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	8/12/2025 (Estimated)
BYSI BeyondSpring	-$11.12M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
KURA Kura Oncology	-$173.98M	-$2.10	N/A	N/A	N/A	N/A	-43.62%	-29.13%	8/6/2025 (Estimated)
MGTX MeiraGTx	-$147.79M	-$2.32	N/A	17.39	N/A	-484.90%	-241.05%	-62.93%	8/11/2025 (Estimated)

Latest BYSI, MGTX, BCAX, and KURA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	BCAX Bicara Therapeutics	-$0.40	-$0.68	-$0.28	-$0.68	N/A	N/A
5/13/2025	Q1 2025	MGTX MeiraGTx	-$0.38	-$0.51	-$0.13	-$0.51	$4.44 million	$1.93 million
5/12/2025	Q1 2025	BYSI BeyondSpring	N/A	-$0.06	N/A	$0.11	N/A	N/A
5/1/2025	Q1 2025	KURA Kura Oncology	-$0.51	-$0.66	-$0.15	-$0.66	$39.08 million	$14.11 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCAX Bicara Therapeutics	N/A	N/A	N/A	N/A	N/A
BYSI BeyondSpring	N/A	N/A	N/A	N/A	N/A
KURA Kura Oncology	N/A	N/A	N/A	N/A	N/A
MGTX MeiraGTx	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCAX Bicara Therapeutics	N/A	24.62	24.62
BYSI BeyondSpring	N/A	2.49	2.49
KURA Kura Oncology	0.02	8.07	8.07
MGTX MeiraGTx	2.34	1.53	1.51

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCAX Bicara Therapeutics	N/A
BYSI BeyondSpring	40.29%
KURA Kura Oncology	N/A
MGTX MeiraGTx	67.48%

Insider Ownership

Company	Insider Ownership
BCAX Bicara Therapeutics	15.50%
BYSI BeyondSpring	29.31%
KURA Kura Oncology	6.40%
MGTX MeiraGTx	7.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCAX Bicara Therapeutics	32	54.54 million	46.08 million	N/A
BYSI BeyondSpring	80	40.32 million	28.50 million	Optionable
KURA Kura Oncology	130	86.57 million	81.03 million	Optionable
MGTX MeiraGTx	300	80.36 million	74.34 million	Optionable

BYSI, MGTX, BCAX, and KURA Headlines

Recent News About These Companies

3 Promising Genomics Stocks to Keep an Eye On in 2025

June 27 at 9:06 AM | zacks.com

MeiraGTx Holdings plc (NASDAQ:MGTX) Shares Sold by Millennium Management LLC

June 11, 2025 | marketbeat.com

MeiraGTx (NASDAQ:MGTX) Trading Up 7.2% - Here's What Happened

June 10, 2025 | marketbeat.com

MeiraGTx (NASDAQ:MGTX) Shares Gap Up - Here's What Happened

June 9, 2025 | marketbeat.com

Short Interest in MeiraGTx Holdings plc (NASDAQ:MGTX) Increases By 16.9%

June 5, 2025 | marketbeat.com

Nuveen Asset Management LLC Boosts Stock Holdings in MeiraGTx Holdings plc (NASDAQ:MGTX)

June 5, 2025 | marketbeat.com

Northern Trust Corp Boosts Holdings in MeiraGTx Holdings plc (NASDAQ:MGTX)

May 28, 2025 | marketbeat.com

MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting

May 13, 2025 | globenewswire.com

MeiraGTx Holdings PLC (MGTX) Reports Q1 Loss, Misses Revenue Estimates

May 13, 2025 | zacks.com

MeiraGTx Reports First Quarter 2025 Financial and Operational Results

May 13, 2025 | globenewswire.com

FDA grants RMAT status to MeiraGTx’s Parkinson’s treatment

May 10, 2025 | investing.com

MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson’s Disease

May 9, 2025 | finance.yahoo.com

MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson's Disease

May 9, 2025 | globenewswire.com

Cone Rod Dystrophy Market Report 2025-2030, with Profiles of SparingVision, Beacon Therapeutics, Nanoscope Therapeutics, MeiraGTx, Ascidian Therapeutics, jCyte, BlueRock Therapeutics and more

April 29, 2025 | globenewswire.com

Richard Giroux Sells 24,000 Shares of MeiraGTx Holdings plc (NASDAQ:MGTX) Stock

April 23, 2025 | insidertrades.com

Insider Selling: MeiraGTx Holdings plc (NASDAQ:MGTX) CEO Sells 47,500 Shares of Stock

April 9, 2025 | insidertrades.com

MeiraGTx Holdings: Gaining Regulatory Focus

March 25, 2025 | seekingalpha.com

MeiraGTx Holdings plc (NASDAQ:MGTX) Is Expected To Breakeven In The Near Future

March 24, 2025 | finance.yahoo.com

MeiraGTx Holdings (MGTX) Partners with Hologen for $200M AI-Powered Parkinson’s Treatment

March 18, 2025 | msn.com

MeiraGTx price target raised to $13 from $11 at RBC Capital

March 17, 2025 | markets.businessinsider.com

Meiragtx Holdings (MGTX) Gets a Buy from Evercore ISI

March 17, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BYSI, MGTX, BCAX, and KURA Company Descriptions

Bicara Therapeutics NASDAQ:BCAX

$8.71 -0.10 (-1.14%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$8.75 +0.04 (+0.46%)

As of 06/27/2025 07:47 PM Eastern

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

BeyondSpring NASDAQ:BYSI

$2.45 -0.07 (-2.78%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$2.41 -0.04 (-1.63%)

As of 06/27/2025 05:06 PM Eastern

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.

Kura Oncology NASDAQ:KURA

$5.67 -0.06 (-1.05%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$5.78 +0.11 (+1.94%)

As of 06/27/2025 06:33 PM Eastern

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

MeiraGTx NASDAQ:MGTX

$6.61 -0.06 (-0.90%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$6.61 0.00 (0.00%)

As of 06/27/2025 05:59 PM Eastern

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time